How Durable Are CAR T-Cell Therapies?March 1st 2018
The use of chimeric antigen receptor (CAR) T-cell therapies for the treatment of hematologic malignancies is still in its early stages, but when the FDA approved tisagenlecleucel and axicabtagene ciloleucel in 2017, this gave hope to oncologists and patients with some types of leukemia and lymphoma who have exhausted all other options.
Moving the Meter on Ovarian CancerDecember 2nd 2016
Ovarian cancer remains a silent and deadly tumor type with 5-year survival rates that lag far behind those of other gynecologic malignancies. Yet optimism is in the air these days as researchers focus on developing new therapies in 2 key areas: antiangiogenic agents and PARP inhibitors.
The RAS Chase: Gaining Ground Against the Toughest OncogeneMay 24th 2016
The RAS family of genes, implicated in more than 30% of human cancers, has proved to be such a difficult molecular driver to target that researchers have considered it "undruggable." A 3-year-old effort by the National Cancer Institute aims to change that—and is making headway.
Getting to Zero: MRD Yardstick for Myeloma Inches CloserJanuary 29th 2016
Researchers and oncologists are excited about the prospect of MRD becoming equally useful in the assessment and management of patients with multiple myeloma, particularly in light of the development of new, more effective therapies and the current limited ability to assess their effectiveness.